Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026

Altimmune announced that its RECLAIM Phase 2 trial data for pemvidutide, a dual glucagon/GLP-1 receptor agonist, in treating alcohol use disorder (AUD) has been accepted as a late-breaking oral presentation at AASLD The Liver Meeting 2026. The trial met its primary endpoint of reducing heavy drinking days and key secondary endpoints. The company is scheduled to meet with the FDA in December for an End-of-Phase 2 meeting to discuss Phase 3 registrational plans.